Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ARV-771 |
Synonyms | |
Therapy Description |
ARV-771 is a bifunctional molecule that targets BET proteins for proteolytic degradation, resulting in reduced target gene expression and potentially leading to increased apoptosis and reduced tumor growth (PMID: 31217338, PMID: 27274052, PMID: 30575820). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ARV-771 | ARV 771|ARV771 | BET Inhibitor (Pan) 32 | ARV-771 is a bifunctional molecule that targets BET proteins for proteolytic degradation, resulting in reduced target gene expression and potentially leading to increased apoptosis and reduced tumor growth (PMID: 31217338, PMID: 27274052, PMID: 30575820). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
VHL H110L | colon carcinoma | sensitive | ARV-771 | Preclinical - Cell culture | Actionable | In a preclinical study, ARV-771 inhibited viability in a colon carcinoma cell line expressing VHL H110L in culture (PMID: 36329119). | 36329119 |
VHL Y112C | leukemia | resistant | ARV-771 | Preclinical - Cell culture | Actionable | In a preclinical study, a leukemia cell line demonstrated resistance to ARV-771 and was found to have acquired VHL Y112C in culture (PMID: 36329119). | 36329119 |
VHL S139fs | leukemia | resistant | ARV-771 | Preclinical - Cell culture | Actionable | In a preclinical study, a leukemia cell line demonstrated resistance to ARV-771 and was found to have acquired VHL S139fs in culture (PMID: 36329119). | 36329119 |
VHL Y112C | colon carcinoma | resistant | ARV-771 | Preclinical - Cell culture | Actionable | In a preclinical study, a colon carcinoma cell line expressing VHL Y112C was resistant to ARV-771 in culture (PMID: 36329119). | 36329119 |
VHL W117* | leukemia | resistant | ARV-771 | Preclinical - Cell culture | Actionable | In a preclinical study, a leukemia cell line demonstrated resistance to ARV-771 and was found to have acquired VHL W117* in culture (PMID: 36329119). | 36329119 |
VHL S111R | leukemia | resistant | ARV-771 | Preclinical - Cell culture | Actionable | In a preclinical study, a leukemia cell line demonstrated resistance to ARV-771 and was found to have acquired VHL S111R in culture (PMID: 36329119). | 36329119 |
VHL V166F | leukemia | resistant | ARV-771 | Preclinical - Cell culture | Actionable | In a preclinical study, a leukemia cell line demonstrated resistance to ARV-771 and was found to have acquired VHL V166F in culture (PMID: 36329119). | 36329119 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|